DelveInsight has launched a new report on “Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast–2030”.
Some facts of the report:
- Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017– 2030.
- DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017
- Among the EU-5 countries, Germany had the highest incident population of ARDS with 148,302 cases.
- Among the EU-5 countries, Spain had the lowest incident population of 20,839 in 2017.
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.
“The highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS”
Scope of the Report
- The Acute Respiratory Distress Syndrome (ARDS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Acute Respiratory Distress Syndrome (ARDS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Acute Respiratory Distress Syndrome (ARDS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Acute Respiratory Distress Syndrome (ARDS)
- The report provides the segmentation of the Acute Respiratory Distress Syndrome (ARDS) epidemiology
KOL- Views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Respiratory Distress Syndrome (ARDS)?
- What are the key findings pertaining to the Acute Respiratory Distress Syndrome (ARDS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Acute Respiratory Distress Syndrome (ARDS) across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Acute Respiratory Distress Syndrome (ARDS)?
- What are the currently available treatments of Acute Respiratory Distress Syndrome (ARDS)?
Reasons to buy
- The Acute Respiratory Distress Syndrome (ARDS) Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) market
- Quantify patient populations in the global Acute Respiratory Distress Syndrome (ARDS) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acute Respiratory Distress Syndrome (ARDS) therapeutics in each of the markets covered
- Understand the magnitude of Acute Respiratory Distress Syndrome (ARDS) population by its epidemiology
- The Acute Respiratory Distress Syndrome (ARDS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient populatio
Table of Contents:
1. Key Insights
2. Executive Summary of Acute Respiratory Distress Syndrome (ARDS)
3. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Acute Respiratory Distress Syndrome (ARDS) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Acute Respiratory Distress Syndrome (ARDS) Treatment and Management
6.2. Acute Respiratory Distress Syndrome (ARDS) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
